This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gear Up for Cencora (COR) Q3 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top-and-bottom-line estimates for Cencora (COR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
SYK Stock Falls Despite Q2 Earnings & Sales Beat, '25 View Up
by Zacks Equity Research
SYK's second-quarter results reflect strong segmental performance, along with a rise in operating margin.
Will Healthcare Growth Help STE Beat on Q1 Earnings?
by Zacks Equity Research
STERIS is likely to have experienced a strong Q1 with 14.3% EPS growth as Healthcare and AST segments show solid momentum.
BAX Stock Falls Following Q2 Earnings & Sales Miss, '25 EPS View Down
by Zacks Equity Research
Baxter misses on Q2 earnings and sales, trims full-year EPS view, and posts weaker gross margin. Shares slide nearly 9% pre-market.
CVS Stock Up on Q2 Earnings & Revenue Beat, '25 EPS View Raised
by Zacks Equity Research
CVS Health beats on Q2 earnings and raises 2025 EPS outlook, lifting shares nearly 8% on strong segment growth and margin gains.
Progyny (PGNY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Progyny (PGNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DexCom Stock Falls Despite Q2 Earnings Beat & 2025 Sales View Raise
by Zacks Equity Research
DXCM beats on Q2 earnings and raises 2025 sales guidance, but shares dip as margin pressure dampens investor enthusiasm.
ALGN Stock Falls on Q2 Earnings and Revenue Miss, Margins Down
by Zacks Equity Research
Align Technology tumbles 34.2% after Q2 earnings and revenues miss estimates as Clear Aligner sales drop and margins tighten further.
Cencora (COR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River Q2 Earnings Preview: What's in Store for the Stock?
by Zacks Equity Research
CRL gears up for Q2 earnings with expected revenue and EPS declines amid mixed segment performance.
Teladoc (TDOC) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of +29.63% and +1.77%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
WGS Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 Sales View
by Zacks Equity Research
GeneDx reports strong Q2 results with record revenues and surging profits. A raised 2025 sales outlook fuels a 26% stock jump.
Are Medical Stocks Lagging McKesson (MCK) This Year?
by Zacks Equity Research
Here is how McKesson (MCK) and Cencora (COR) have performed compared to their sector so far this year.
Will SYK's Q2 Earnings Reflect Strong Growth Despite Tariff Overhang?
by Zacks Equity Research
Stryker's second-quarter 2025 results are expected to reflect strong segmental performance. However, rising costs and tariffs are likely to have continued to hurt margins.
Henry Schein to Report Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
HSIC eyes modest Q2 gains, with dental, medical and specialty segments showing signs of steady momentum.
Baxter Q2 Preview: Can Core Segments Deliver Another Solid Quarter?
by Zacks Equity Research
BAX aims for modest Q2 growth as core segments build on Q1 momentum and margin gains stabilize after recent recovery.
Should You Buy, Sell, or Hold GE Healthcare Before Q2 Earnings?
by Zacks Equity Research
GEHC leans on Imaging and PDx strength for Q2, but tariff headwinds and margin pressures could test investor confidence.
RVTY Posts Q2 Earnings & Sales Beat, Raises '25 Sales View
by Zacks Equity Research
Revvity's second-quarter results showcase strong growth in its Diagnostics business, along with recovery in Life Sciences segmental sales.
Will Exome and Genome Growth Boost WGS' Q2 Earnings?
by Zacks Equity Research
GeneDx is likely to have experienced a Q2 lift, backed by strong Exome and genome test volumes, new indications and strategic tech moves.
IDEXX to Release Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
IDXX eyes a Q2 earnings jump with CAG growth, global pricing gains, and momentum in water and software segments.
Integer Holdings Q2 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
ITGR posts strong second-quarter revenue growth, but EPS misses estimate despite solid segment momentum.
EW Stock Climbs on Q2 Earnings & Revenue Beat, Margins Down
by Zacks Equity Research
Edwards Lifesciences posts a second-quarter 2025 earnings and revenue beat, with strong growth in TAVR and TMTT segments despite margin pressure.
Revvity Q2 Preview: Can Strong Segments Deliver an Earnings Beat?
by Zacks Equity Research
RVTY is likely to see another earnings beat as Diagnostics momentum and Signals Software growth offset tariff headwinds.
WST Stock Rises on Q2 Earnings Beat, EPS View Up on Tariff & FX Benefit
by Zacks Equity Research
West Pharmaceutical's second-quarter top line continues to benefit from revenue growth in its Proprietary Products segment.
Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact?
by Zacks Equity Research
DexCom Q2 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.